Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
24 hedge funds and large institutions have $25.6M invested in Evofem Biosciences, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 9 closing their positions.
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
14% more funds holding
Funds holding: 21 → 24 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less capital invested
Capital invested by funds: $28.5M → $25.6M (-$2.91M)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Amici Capital
New York
|
+$2.14M |
| 2 |
GTC
Ghost Tree Capital
New York
|
+$307K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$195K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$191K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$184K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.26M |
| 2 |
PSC
Piper Sandler & Co
Minneapolis,
Minnesota
|
-$1.79M |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$1.47M |
| 4 |
CPCM
Clifton Park Capital Management
Wilmington,
Delaware
|
-$1.01M |
| 5 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$969K |
EVFM Hedge Fund Activity: Q2 2015 in Review
24 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q2 2015, worth a combined $25.6M — down 10% from $28.5M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new EVFM positions and 9 closed out — a net gain of 3 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Amici Capital, opening a new position worth an estimated $2.14M. The largest seller was Federated Hermes, exiting entirely with an estimated $2.26M sold.
- 24 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q2 2015, up from 21 in Q1 2015.
- Funds reported $25.6M of Evofem Biosciences, Inc. Common Stock stock for Q2 2015, down 10% quarter-over-quarter.
- 12 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q2 2015 and 9 closed out, a net change of +3 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q2 2015 was Amici Capital, an estimated $2.14M added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q2 2015 was Federated Hermes, an estimated $2.26M sold.
Based on aggregated 13F filings for Q2 2015.